TXMD

Therapeuticsmd Inc

• Benzinga·05/12 21:47

  TherapeuticsMD Says Company Continues To Evaluate Strategic Alternatives, Including Acquisition Or Merger

• TipRanks·05/12 20:47

  TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

• Seeking Alpha·05/12 20:24

  Therapeutics MD reports Q1 results

• Reuters·05/12 20:13

  TherapeuticsMD swings to Q1 net income as license revenue rises

• PUBT·05/12 20:08

  TherapeuticsMD swings to FY26 Q1 profit of $103,000; revenue rises 84.2% to $724,000

• Reuters·05/12 20:05

  THERAPEUTICSMD INC - COMPANY CONTINUES TO EVALUATE STRATEGIC ALTERNATIVES INCLUDING ACQUISITION OR MERGER

• Dow Jones·04/27 20:33

  TherapeuticsMD Inc. Stock Sheds 5.5%, Underperforms Market

• Dow Jones·04/06 20:32

  TherapeuticsMD Inc. Stock Rallies 10.0%, Outperforms Market

• TipRanks·04/01 15:39

  TherapeuticsMD Explains Brief Delay In Annual Filing

• Reuters·04/01 10:08

  TherapeuticsMD delays 2025 10-K after filing omits auditor report

• TipRanks·03/31 00:12

  TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

• Benzinga·03/30 22:10

  TherapeuticsMD Q4 EPS $(0.06) Down From $0.01 YoY, Sales $893.000K Up From $667.000K YoY

• Dow Jones·03/30 20:34

  TherapeuticsMD Inc. Stock Slides 5.2%, Underperforms Market

• TipRanks·03/30 20:23

  TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year

• Seeking Alpha·03/30 20:15

  Therapeutics MD reports FY results